VistaGen’s deal with Pherin Pharmaceuticals to develop PH-94B has positioned the Company to grab a healthy share of, social anxiety, and major depression markets.

VistaGen and the FDA reached consensus on key aspects of a unique initial pivotal Phase 3 clinical trial of PH94B involving a single-event, laboratory-simulated public speaking challenge in adult patients with SAD.

VistaGen of South San Francisco out-licensed China/Southeast Asia rights for a novel anxiety treatment to EverInsight Therapeutics, a China in-licensing company, in a $177 million agreement.

The collaboration is intended to support Phase 3 development and commercialization of PH94B in key Asian markets. The agreement includes a $5 million upfront payment and development and commercial milestones up to $172 million.

VistaGen's drug AV-101 has breakthrough potential for treatment of depression and other indications.

I think VistaGen's stock has tremendous upside potential that today's price. The company is likely to raise cash at some point over the next several months.

On February 13, 2017, VistaGen Therapeutics provided a business and financial update following results of the quarter ending December 31, 2016. Here is a quick review of some of the recent happenings at the company.

The agreement provides some nice potential upside in terms of future milestones and royalties from BlueRock. It also provides VistaGen a roadmap to monetize other aspects of its hPSC platform for cell therapy and regenerative medicine applications.

Abilify is the single best-selling CNS drug of all time, but it's clearly not perfect. VistaGen Therapeutics looks to build upon the success of Abilify with a new approach to neurological disorders with Phase 2 candidate, AV101.